Send to

Choose Destination
Int J Med Sci. 2020 Jan 14;17(2):234-241. doi: 10.7150/ijms.38363. eCollection 2020.

Progress in Hematopoietic Stem Cell Transplantation for CIDP.

Author information

Department of Neurology, The Second Xiangya Hospital, Central South University, Renmin Road 139#, Changsha, 410011, Hunan, China.
Healing With Stem Cell Therapy Inc, PO Box 2289, Shawnee Mission, 66201, KS, USA.


Chronic inflammatory demyelinating polyneuropathy (CIDP) is a kind of autoimmune-mediated inflammation and demyelinating disease. The etiology is mainly related to autoimmune dysfunction. The conventional treatments of CIDP have relied on immunomodulation and inhibition therapies such as adrenal cortex hormone, intravenous immunoglobulin (IVIg) and plasma exchange. Hematopoietic stem cell transplantation (HSCT) is known as a novel therapy for autoimmune disorders, which provides the chance to cure CIDP. More than 70 patients with refractory CIDP have received HSCT. The clinical symptoms and electrophysiological examination results of most patients have been improved. However, the treatment still has risks. This review describes the pathogenesis of CIDP and the current conventional treatments, and highlights the application of HSCT in CIDP, including its efficacy and safety.


Chronic inflammatory demyelinating polyneuropathy; Hematopoietic stem cell transplantation; autoimmune diseases; demyelinating neuropathy

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Publication type

Publication type

Supplemental Content

Full text links

Icon for Ivyspring International Publisher Icon for PubMed Central
Loading ...
Support Center